NRX Pharmaceuticals, Inc. (NRXP) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to the NRX Pharmaceuticals Q3 2025 Earnings Conference Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Monday, November 17, 2025. I would now like to turn the conference over to Matthew Duffy, Chief Business Officer. Please go ahead. Thank you, Joelle, and welcome everyone. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U.S. federal security laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports filed with the SEC. The forward-looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise forward-looking statements. Information presented on this call is contained in the press release issued this morning and in the company's Form 10-Q, which may be accessed from the investors page of the NRX Pharmaceuticals, Inc. website. Joining me on the call today are Dr. Jonathan Javitt, our founder, chairman, and CEO, and Michael Abrams, our chief financial officer. We'll provide an overview of our company's progress as reported in today's 10Q, following which Mike will give a review of the company's financials and results. Following their prepared results, we'll address investor ques...